HomeAgenda

PartnershipUpdated on 8 September 2025

EXORPHIA is seeking partners for EV therapeutics & delivery (EXP01, EXP03) and an IVF adjunct.

About

EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.

Our lead pipeline comprises three pillars:

 (1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)

 (2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)

(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).

Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.

We would be pleased to discuss our programs in more detail at the event.

Organisation

EXORPHIA, INC.

Company (SME/startup) / 中小企業・スタートアップ

Tokyo, Japan